Your browser doesn't support javascript.
loading
Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.
Wu, Y; Amonkar, M M; Sherrill, B H; O'Shaughnessy, J; Ellis, C; Baselga, J; Blackwell, K L; Burstein, H J.
Afiliação
  • Wu Y; Biometrics Department, Research Triangle Institute Health Solutions, Research Triangle Park. Electronic address: ywu@rti.org.
  • Amonkar MM; Global Health Outcomes, Oncology, GlaxoSmithKline, Collegeville.
  • Sherrill BH; Biometrics Department, Research Triangle Institute Health Solutions, Research Triangle Park.
  • O'Shaughnessy J; Baylor Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, USA.
  • Ellis C; Global Health Outcomes, Oncology, GlaxoSmithKline, Collegeville.
  • Baselga J; Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Blackwell KL; Duke University Medical Center, Durham.
  • Burstein HJ; Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
Ann Oncol ; 22(12): 2582-2590, 2011 Dec.
Article em En | MEDLINE | ID: mdl-21406472

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 / Resistencia a Medicamentos Antineoplásicos Tipo de estudo: Clinical_trials Aspecto: Patient_preference Limite: Female / Humans Idioma: En Revista: Ann Oncol Ano de publicação: 2011 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 / Resistencia a Medicamentos Antineoplásicos Tipo de estudo: Clinical_trials Aspecto: Patient_preference Limite: Female / Humans Idioma: En Revista: Ann Oncol Ano de publicação: 2011 Tipo de documento: Article